RepliCel Life Sciences Inc (REPCF)
0.0428
0.00 (0.00%)
USD |
OTCM |
May 03, 16:00
RepliCel Life Sciences Profit Margin (Quarterly): -925.7% for Sept. 30, 2023
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
Date | Value |
---|---|
September 30, 2023 | -925.7% |
June 30, 2023 | -631.2% |
March 31, 2023 | -1.09K% |
December 31, 2022 | |
September 30, 2022 | -1.26K% |
June 30, 2022 | -1.26K% |
March 31, 2022 | -890.3% |
December 31, 2021 | -941.9% |
September 30, 2021 | -945.4% |
June 30, 2021 | -1.19K% |
March 31, 2021 | -1.53K% |
December 31, 2020 | -287.7% |
September 30, 2020 | -676.2% |
June 30, 2020 | -395.0% |
March 31, 2020 | -427.9% |
December 31, 2019 | -709.1% |
September 30, 2019 | -666.7% |
June 30, 2019 | -1.49K% |
March 31, 2019 | -1.31K% |
December 31, 2018 | -552.9% |
September 30, 2018 |
Date | Value |
---|---|
June 30, 2018 | |
March 31, 2018 | |
December 31, 2017 | |
September 30, 2017 | |
June 30, 2017 | |
March 31, 2017 | |
December 31, 2016 | |
September 30, 2016 | |
June 30, 2016 | |
March 31, 2016 | |
December 31, 2015 | |
September 30, 2015 | |
June 30, 2015 | |
March 31, 2015 | |
December 31, 2014 | |
September 30, 2014 | |
June 30, 2014 | |
March 31, 2014 | |
December 31, 2013 | |
September 30, 2013 | 63.43% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-1.53K%
Minimum
Mar 2021
-287.7%
Maximum
Dec 2020
-900.6%
Average
-925.7%
Median
Sep 2023
Profit Margin (Quarterly) Benchmarks
Acasti Pharma Inc | -- |
Aurinia Pharmaceuticals Inc | -59.60% |
Edesa Biotech Inc | -- |
Lexaria Bioscience Corp | -448.0% |
InMed Pharmaceuticals Inc | -119.2% |
Profit Margin (Quarterly) Related Metrics
Return on Assets | -13.90% |
Operating Margin (Quarterly) | -368.1% |
Return on Net Operating Assets | -48.23% |